Immuno-Oncology | Specialty

The Emergence of PD-L1 Inhibitors

July 6th 2016

Combined Targeting Against VEGF and PD-1 in Bladder Cancer

July 6th 2016

The FDA Approval of Atezolizumab in Bladder Cancer

July 6th 2016

PD-1 Inhibitor Use in Melanoma

July 6th 2016

PD-1 Inhibitor Use in Kidney and Bladder Cancers

July 6th 2016

PD-1 Inhibitor Use in Advanced Lung Cancer

July 6th 2016

Adoptive Cell Therapy and Antibodies

July 6th 2016

Immunotherapy Modalities: Checkpoint Inhibitors and Vaccines

July 6th 2016

The Immune System and Cancer Pathogenesis

July 6th 2016

Dr. Keith Kerr on Selecting Patients for Immunotherapy in Lung Cancer

July 6th 2016

Immunotherapy Perspective From a PD-1 Pioneer

July 5th 2016

Suzanne L. Topalian, MD, discusses progress in PD-1/PD-L1 immunotherapies and the prospects for developing biomarkers to better identify patients who would benefit from the new agents.

Nivolumab Spurs Encouraging Responses in Metastatic Anal Cancer

July 2nd 2016

The first prospective study to investigate the use of immunotherapy in patients with squamous cell carcinoma of the anal canal demonstrated promising results following treatment with nivolumab.

Dr. Bauml on KEYNOTE-055 Study for Patients With HNSCC

June 30th 2016

Joshua M. Bauml, MD, assistant professor of Medicine, Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, discusses the preliminary results of the KEYNOTE-055 study, which investigated pembrolizumab (Keytruda) after failure on platinum-based therapy and cetuximab in patients with head and neck squamous cell carcinoma.

Dr. Spigel on CheckMate-331 Trial for SCLC

June 29th 2016

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the ongoing CheckMate-331 trial, which is investigating nivolumab (Opdivo) versus chemotherapy in relapsed patients with small cell lung cancer (SCLC) after first-line platinum-based chemotherapy.

KEYNOTE-012 Investigator Explains Promise of Pembrolizumab in HNSCC

June 29th 2016

Ranee Mehra, MD, discusses what the KEYNOTE-012 findings could mean for patients, the growing role for the immunotherapy agent in head and neck cancer, and what else is on the horizon for the treatment landscape.

CHMP Recommends Approval of Pembrolizumab for Lung Cancer

June 28th 2016

The EMA's Committee for Medicinal Products for Human Use has granted a positive opinion for use of pembrolizumab (Keytruda) as a treatment for patients with locally advanced or metastatic PD-L1-positive non–small cell lung cancer.

FDA Grants Nivolumab Breakthrough Designation for Advanced Bladder Cancer

June 28th 2016

The FDA has granted nivolumab (Opdivo) a breakthrough therapy designation for the treatment of patients with unresectable locally advanced or metastatic urothelial carcinoma after the failure of a platinum-containing regimen.

Dr. Andtbacka on Optimal Use of T-VEC in Melanoma

June 27th 2016

Robert Andtbacka, MD, associate professor in the Division of Surgical Oncology, Department of Surgery at the University of Utah School of Medicine, discusses the optimal use of talimogene laherparepvec (T-VEC) in patients with melanoma.

First-in-Human CRISPR Immunotherapy Would Target PD-1

June 24th 2016

At a time when PD-1 inhibitors are dominating the immunotherapy field, a team of researchers is seeking to use groundbreaking CRISPR gene editing technology for the first time in human beings to create an engineered T-cell agent that would knock out the gene that controls the immune checkpoint’s activity.

Expert Sheds Light on Promising Immunotherapy Combo Data in mCRC

June 23rd 2016

Michael J. Overman, MD, discusses the findings of the phase II CheckMate-142 study, which examined nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with high microsatellite instability colorectal cancer.